Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 5/20 | 0.54 |
| ▸ | CCR1 | P32246 | 11/20 | 0.51 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | DDT | P30046 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5438320 | 0.90 | CCR1 (0.53) | ELANECCR1PLA2G10DDT | |
| SCHEMBL5440126 | 0.88 | DDT (0.51) | ELANECCR1PLA2G10DDT | |
| SCHEMBL5757244 | 0.85 | ELANE (0.67) | ELANECCR1ALDH1A1MAPTDDT | |
| SCHEMBL5445075 | 0.84 | ELANE (0.52) | ELANECCR1PLA2G10 | |
| SCHEMBL5438329 | 0.84 | ELANE (0.59) | ELANECCR1PLA2G10ALDH1A1MAPT | |
| SCHEMBL5443539 | 0.84 | SORT1 (0.56) | ELANECCR1PLA2G10ALDH1A1 | |
| SCHEMBL31490289 | 0.84 | ELANE (0.60) | ELANECCR1ALDH1A1MAPTRXFP1 | |
| SCHEMBL561082 | 0.84 | ELANE (0.60) | ELANECCR1ALDH1A1MAPTRXFP1 | |
| SCHEMBL5440472 | 0.84 | DDT (0.56) | ELANECCR1PLA2G10ALDH1A1DDT | |
| SCHEMBL5445052 | 0.83 | ELANE (0.46) | ELANECCR1PLA2G10ALDH1A1DDT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010551-A1 | Quinoline derivatives as neutrophil elastase inhibitors and their use | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010551-A1 | Quinoline derivatives as neutrophil elastase inhibitors and their use | SERPINB1, ELANE, MPO | ELANE 2/4885CCR1 200/4885PLA2G10 1148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.